This is a National, Multicentre, Observational Registry to study adherence and long term outcomes of therapy in paediatric subjects using Easypod™ electromechanical device for growth hormone treatment from hospitals in Greece and to assess the level of adherence of subjects receiving SAIZEN® via Easypod™.
Subjects will be enrolled in a multicenter, longitudinal observational registry. Parents/subjects will provide their Informed Consent/assent to upload their data for populationbased analyses and optionally to adhere to a patient adherence support program designed to improve their adherence and, ultimately, clinical outcomes. Adherence data will be primarily derived from the Easypod™ device combined with physician data entry of outcome measures. Data will be collected retrospectively and prospectively. This will allow the establishment of adherence profiles and explore the hypothesis that patient adherence support programs improve adherence and subsequent clinical outcomes. Collected data will be also analyzed in a multinational pooled analysis of comparable national studies. Primary Objective: \- To assess the level of adherence of subjects receiving SAIZEN® via Easypod™ Secondary Objectives: * To identify adherence subject profiling * To describe the impact of adherence on clinical outcomes for subject receiving SAIZEN® via Easypod™ * To asses the impact of adherence on Insulin-like Growth Factor 1 (IGF1) (i.e. above, below or within normal ranges) * To assess/describe the impact of the Greek Scientific Service (Patient Support Program)
Study Type
OBSERVATIONAL
Enrollment
180
Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
For Recruiting Locations in Greece,
Please Contact the Merck KGaA Communication Center, Greece
Mean percent of adherence by subject
Time frame: At least 6 months and up to 5 years
Correlation of adherence and growth outcome after each year of SAIZEN® treatment with Easypod™
Correlation of adherence and growth outcome (height velocity (HV), height velocity-standard deviation score (HV-SDS), height, change in height (height SDS) after each year of SAIZEN® treatment with Easypod™
Time frame: At least 6 months and up to 5 years
Subject adherence profile based on age, gender, indication, self-injection or not, time on treatment
Time frame: At least 6 months and up to 5 years
Correlation of adherence with current IGF-I status (i.e. above, below or within normal ranges)
Time frame: At least 6 months and up to 5 years
Impact of Greek Scientific Service (Patient Support Program) on adherence and outcomes for subjects using Easypod™.
Time frame: At least 6 months and up to 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.